Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of some more news that didn’t make the cut. Mostly funding, partnerships and alliances, and clinical trials this week…

More News-MEDICALheader

  • French biotech Sensorion is starting a Phase II trial of its candidate drug for sudden hearing loss
  • Immunocore, a British biotech focusing on immuno-oncology, has started a Phase I study of its solid tumor candidate developed as part of its collaboration with GSK, triggering an undisclosed milestone payment
  • French virus-based immunotherapy company Transgene sold the Greater China rights for its candidate cancer and chronic hepatitis B vaccines for $48M (€41M) to Chinese Tasly Biopharmaceuticals
  • Genkyotex, a Geneva-based biotech, raised €7.5M in gross financing to fund further development of its lead candidate for the autoimmune liver disease primary biliary cholangitis.
  • German-biotech Medigene is partnering with US-biotech Structured Immunity to develop a T cell receptor candidate for targeting solid tumors by combining expertise form both companies
  • Experts from the European Society for Medical Oncology have created a tumor DNA scale to help clinicians choose the best treatment for their patients tailored to the type of cancer that they have
  • Well-known German biotech Evotec has gone into a strategic research alliance with Danish diabetes giant Novo Nordisk to co-develop small molecule therapies for diabetes, obesity, nonalcoholic steatohepatitis, cardiovascular diseases and diabetic kidney disease
  • UK-based Compass Pathways, a company developing treatments based on magic mushroom key ingredient psilocybin, have FDA approval to begin clinical trials in the US and a Phase II trial in Europe and North America will begin very soon
  • A study lead by French biotech OSE Immunotherapeutics shows that its candidate drug, aimed at targeting autoimmune disease and transplantation patients, is able to block graft-versus-host disease in non-human primates
  • uniQure, a Dutch gene therapy company, has started enrolling patients in a Phase IIb study of its gene therapy for patients with severe hemophilia B
  • In a step forward for those enthusiastic about using the new super material graphene to make medical devices and implants, European scientists found that it can be biodegraded by myeloperoxidase, an enzyme that occurs naturally in the human body.
  • The European Commission granted marketing authorisation for Eisai and Merck’s new first line treatment Levima (lenvatinib) for advanced hepatocellular carcinoma
  • Swiss-biotech Novaremed raised CHF6M (€5.3M) in additional financing to prepare for a Phase IIb clinical study of its lead drug candidate for Diabetic Neuropathic Pain

Policy, legal, finance

ADVERTISEMENT


Images: Shutterstock

Previous post

Shire gets US market approval for rare inflammatory disease drug

Next post

Are Fungi the Answer to a More Sustainable Future?

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.